Cytarabine
Quick Overview
| Attribute | Value |
|---|---|
| Drug Name | Cytarabine |
| DrugBank ID | DB00987 |
| KG Predictions | 60 |
| DL Predictions (≥0.7) | 205 |
| Evidence Level | L5 |
| NPRA Status | Approved |
Sample Brand Names in Malaysia
Predicted Indications
This drug has 60 knowledge graph predictions and 205 high-confidence deep learning predictions.
Top KG Predictions
| Indication | Source |
|---|---|
| acute myeloid leukemia with minimal differentiation | KG |
| leukemia, lymphocytic, susceptibility to | KG |
| acute myeloblastic leukemia without maturation | KG |
| therapy related acute myeloid leukemia and myelodysplastic syndrome | KG |
| acute myeloblastic leukemia with maturation | KG |
| acute myeloid leukemia with t(8;21)(q22;q22) translocation | KG |
| acute myeloid leukemia with CEBPA somatic mutations | KG |
| acute lymphoblastic/lymphocytic leukemia | KG |
| myeloid leukemia | KG |
| inherited acute myeloid leukemia | KG |
FHIR Resources
Access drug data via FHIR R4 API:
- MedicationKnowledge:
/fhir/MedicationKnowledge/DB00987
Related Resources
| Resource | Link |
|---|---|
| DrugBank | View on DrugBank |
| PubMed | Search PubMed |
| ClinicalTrials.gov | Search Trials |
Disclaimer
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.
Drug repurposing predictions are for research purposes only. These predictions have not been clinically validated and should not be used for medical decisions. Always consult healthcare professionals.